Remarkable Response to Immunotherapy and VEGFR Inhibitor in Xp11 Translocation Renal Cell Carcinoma in a 17‐Year‐Old Adolescent
Piyarat Limpawittayakul, Narongchai Teerayathanakul, Farid Cherbal · 2026
Read Remarkable Response to Immunotherapy and VEGFR Inhibitor in Xp11 Translocation Renal Cell Carcinoma in a 17‐Year‐Old Adolescent by Piyarat Limpawittayakul, Narongchai Teerayathanakul, Farid Cherbal (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13389439.txt.
Description
Piyarat Limpawittayakul and co-authors report, in 2026, a striking treatment response in a 17-year-old girl with a rare kidney cancer. The cancer, Xp11 translocation renal cell carcinoma, involves a fusion of the TFE3 gene, makes up fewer than five percent of kidney cancers, and had already spread widely.
The teenager arrived with a large left kidney mass, blood in her urine, and spread to lymph nodes and the chest lining. Staining confirmed the TFE3 marker and sequencing named the fusion. She then received pembrolizumab together with lenvatinib, an immune drug paired with a blood vessel blocker. Oncologists gain a detailed single-case account for a cancer where no standard plan for spread disease yet exists.
Catalog record
| CREATOR | Piyarat Limpawittayakul, Narongchai Teerayathanakul, Farid Cherbal |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 18286 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |